• Imagin Medical Inc.’s patented i/Blue System revolutionizes the way surgeons are able to visualize the bladder and identify cancers during surgery
• The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies
• Bladder cystoscopies first target – multiple other endoscopic procedures planned

Science and technology have continued to make striking advancements in cancer therapeutics and treatment protocols, improving upon on past successes and creating better outcomes for cancer patients. A prime example is an exciting new development in visualizing cancer during minimally invasive surgeries. Surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF), is establishing a new paradigm in a doctor’s ability to “see” and surgically treat cancers. With bladder cancer as its first target, Imagin Medical’s initial product is the i/Blue Imaging™ System. The company’s patented, ultrasensitive imaging technology is based on advanced optics and light sensors and employs ultrasensitive imaging technology. Identifying potential early-stage tumors can be difficult because of the inability to distinguish between healthy tissue and tumors when viewed through a scope only using conventional white light.

Cystoscopy is the conventional diagnostic procedure for visualizing bladder cancer during surgery. It allows the doctor to see inside the body with a thin, lighted, flexible tube called a cystoscope which uses white light to illuminate the bladder. White light has been used for decades and is the standard for more than 90% of the market. Like a roadmap with street signs, white light images show the full landscape of the bladder but do not effectively highlight cancer. A promising new modality, blue light cystoscopy, uses blue-filtered white light to detect flat tumors and cancerous cells not seen with white light that may be left behind during surgical removal of the tumor. However, surgeons can’t operate using blue light images. The blue images aren’t in real time, orientation in the bladder is easily lost and the surgeon must manually switch from white to blue cystoscopy and back again.

Both white and blue light cystoscopies have effective uses and serious limitations in seeing the landscape of the bladder and identifying all the cancerous cells during surgery. Missing any cancerous cells poses serious concerns because they will continue to grow and spread to other parts of the bladder, a fact reflected by the recurrence rate of fifty per cent.

The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies. By combining the white and blue light with an FDA-approved imaging agent, the i/Blue System displays side-by-side images in real-time, without the necessity to switch back and forth between the two images. Unlike any other modalities on the market today, Imagin Medical’s i/Blue Imaging System can attach to almost any endoscope model currently in use which creates a plug and play state-of-the-art system adaptable to virtually any clinical setting.

Imagin Medical is advancing the i/Blue Imaging System toward commercialization. The FDA approval process is underway, and the company’s intellectual property is well-protected. Perhaps even more significant, Imagin intends to build on the i/Blue technology which will facilitate entry into multiple other endoscopic procedures. Imagin Medical is improving on past technologies and creating better outcomes for patients while even at a reduced cost.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.investorwire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.